Hydromorphone Hydrochloride Extended-Release Capsules (C-II)

Abstract

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.

Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The January 2005 monograph topics are natalizumab, solifenacin succinate, vincristine sulfate liposomes injection, sodium tetradecyl sulfate injection, and testosterone transdermal. The DUE is on natalizumab.

Get full access to this article

View all access options for this article.

References

Palladone [package insert]. Stamford, CT: Purdue Pharma LP; 2004.

Food and Drug Administration. FDA approves new extended release pain medication. National Press Office; September 24, 2004. Talk Paper T04-40. Available at: http://www.fda.gov/bbs/topics/answers/2004/ans01315.html. Accessed on October 8, 2004.

Food and Drug Administration. FDA Approval Letter: NDA 21-044. Available at: http://www.fda.gov/cder/foi/appletter/2004/21044ltr.pdf. Accessed on October 8, 2004.

OxyContin [package insert]. Stamford, CT: Purdue Pharma L.P.; 2003.

Avinza [package insert]. San Diego, CA: Ligand Pharmaceuticals Inc.; 2003.

MS Contin [package insert]. Stamford, CT: Purdue Frederick Company; 2003.

Kadian [package insert]. Piscataway, NJ: Alpharma Branded Products Division; 2003.

Oramorph SR [package insert]. Columbus, OH: Roxane Laboratories Inc.; 2001.

Drover

D.R.

, Angst

M.S.

, Valle

Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers.

Anesthesiology. 2002; 97(4): 827–836.

10.

Chokshi

, Zia

Hot-melt extrusion technique: a review.

Iranian J Pharma Res. 2004; 3: 3–16.

11.

Hydromorphone HCl. Drug Facts and Comparisons. eFacts [online]. 2004. Available from Wolters Kluwer Health, Inc. Available at: www.factsandcomparisons.com. Accessed on October 2004.

12.

Palangio

, Northfelt

D.W.

, Portenoy

R.K.

Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.

J Pain Symptom Manage. 2002; 23(5): 355–368.

13.

Angst

M.S.

, Drover

D.R.

, Lotsch

Pharmacodynamics of orally administered sustained-release hydromorphone in humans.

Anesthesiology. 2001; 94(1): 63–73.

14.

United States Department of Justice Drug Enforcement Administration: Diversion Control Program. Drugs and Chemicals of Concern: Hydromorphone. October 2004. Available at: http://www.deadiversion.usdoj.gov/drugs_concern/hydromorphone.htm. Accessed on October 8, 2004.